Glucuronidation and covalent protein binding of benoxaprofen and flunoxaprofen in sandwich-cultured rat and human hepatocytes.
Benoxaprofen (BNX), a nonsteroidal anti-inflammatory drug (NSAID) that was withdrawn because of hepatotoxicity, is more toxic than its structural analog flunoxaprofen (FLX) in humans and rats. Acyl glucuronides have been hypothesized to be reactive metabolites and may be associated with toxicity. Both time- and concentration-dependent glucuronidation and covalent binding of BNX, FLX, and ibuprofen (IBP) were determined by exposing sandwich-cultured rat hepatocytes to each NSAID. The levels of glucuronide and covalent protein adduct measured in cells followed the order BNX > FLX > IBP. These results indicate that 1) BNX-glucuronide (G) is more reactive than FLX-G, and 2) IBP-G is the least reactive metabolite, which support previous in vivo studies in rats. The proportional increases of protein adduct formation for BNX, FLX, and IBP as acyl glucuronidation increased also support the hypothesis that part of the covalent binding of all three NSAIDs to hepatic proteins is acyl glucuronide-dependent. Moreover, theses studies confirmed the feasibility of using sandwich-cultured rat hepatocytes for studying glucuronidation and covalent binding to hepatocellular proteins. These studies also showed that these in vitro methods can be applied using human tissues for the study of acyl glucuronide reactivity. More BNX-protein adduct was formed in sandwich-cultured human hepatocytes than FLX-protein adduct, which not only agreed with its relative toxicity in humans but also was consistent with the in vitro findings using rat hepatocyte cultures. These data support the use of sandwich-cultured human hepatocytes as an in vitro screening model of acyl glucuronide exposure and reactivity.
Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Seattle, Washington, USA.
Jennifer Q
JQ
Dong
Philip C
PC
Smith
D000328:Adult; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000378:metabolism*; D001583:Benzoxazoles / Q000378:metabolism* / Q000633:toxicity; D001711:Biotransformation; D018929:Cell Culture Techniques; D003094:Collagen; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005240:Feasibility Studies; D005965:Glucuronates / Q000378:metabolism* / Q000633:toxicity; D014453:Glucuronosyltransferase / Q000378:metabolism; D022781:Hepatocytes / Q000378:metabolism*; D006801:Humans; D007052:Ibuprofen / Q000378:metabolism; D007700:Kinetics; D007797:Laminin; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D008954:Models, Biological; D011422:Propionates / Q000378:metabolism* / Q000633:toxicity; D011485:Protein Binding; D011509:Proteoglycans; D051381:Rats; D017207:Rats, Sprague-Dawley
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001583:Benzoxazoles; D004338:Drug Combinations; D005965:Glucuronates; D007797:Laminin; D011422:Propionates; D011509:Proteoglycans; C059485:matrigel; C011677:benoxaprofen; C055871:benoxaprofen glucuronide; D003094:Collagen; D014453:Glucuronosyltransferase; C045356:flunoxaprofen; D007052:Ibuprofen